Drug Approval | March 01, 2023
Zydus receives final approval from the USFDA for Apixaban Tablets
Apixaban Tablets, 2.5 mg and 5 mg had annual sales of USD 18,876 mn in the United States (IQVIA MAT Dec. 2022).
Apixaban Tablets, 2.5 mg and 5 mg had annual sales of USD 18,876 mn in the United States (IQVIA MAT Dec. 2022).
Receives Subject Expert Committee recommendation to bring new therapies of Pompe, ASMD to India
The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
Ayurveda is one of the most advanced sciences of its times
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
The safety profile of LAGEVRIO in this trial was generally consistent with that observed in previously reported clinical studies
The new sterile filling line meets cGMP aseptic filling regulatory requirements
Cipla has received 8 inspectional observations in Form 483
There is a fast resurgence in the transplant activities post COVID
Subscribe To Our Newsletter & Stay Updated
